Veracyte Inc reports results for the quarter ended December 31 - Earnings Summary

Veracyte

24/02/2025 22:41

* Veracyte Inc  VCYT.OQ  reported quarterly adjusted
earnings of 6
cents​​ per share for the quarter ended December 31, higher than
the same quarter last year, when the company reported EPS of -39
cents.  The mean expectation of twelve analysts for the quarter
was for earnings of 11 cents per share. Wall Street expected
results to range from 5 cents to 15 cents per share.
    * Revenue rose 20.8% to $118.63 million from a year ago;
analysts
expected $116.77 million. 
    * Veracyte Inc's reported EPS for the quarter was 6 cents​.
    * The company reported quarterly net income of $5.11
million.
    * Veracyte Inc shares had fallen by 1.1% this quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Veracyte Inc is
$48.00 
This summary was machine generated from LSEG data February 24 at
10:41 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      0.11           0.06           Missed
 Sep. 30 2024      0.03           0.19           Beat
 Jun. 30 2024      -0.02          0.07           Beat
 Mar. 31 2024      -0.16          -0.02          Beat